Healthcare Services

Global Oncology Companion Diagnostics Market Forecast 2026–2035: Long-Term Growth Insights

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the oncology companion diagnostics market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Oncology Companion Diagnostics Market show for the 2026–2030 period?

The oncology companion diagnostics market has experienced significant expansion in recent years. This market is projected to grow from $3.79 billion in 2025 to $4.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.0%. The historical growth can be attributed to several factors, including the increasing prevalence of cancer types such as breast, colorectal, and melanoma, a growing emphasis on personalized medicine, the escalating demand for targeted therapy selection, the expansion of diagnostic laboratories and hospitals, and advancements in molecular and genetic testing technologies.

The oncology companion diagnostics market size is anticipated to undergo significant expansion in the coming years. It is forecast to reach $6.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. This growth throughout the forecast period is primarily propelled by the increasing adoption of next-generation sequencing (ngs) and pcr-based diagnostics, enhanced collaboration between pharmaceutical and diagnostic companies, an increase in regulatory approvals for companion diagnostics, rising demand for precision oncology, and the expanding use of bioinformatics and decision support software in diagnostics. Prominent trends expected in this period encompass the growing uptake of digital platforms for managing companion diagnostic data, greater integration of artificial intelligence in biomarker analysis and patient stratification, the expanding application of genomics and precision medicine in targeted cancer therapy, heightened automation in diagnostic testing and laboratory workflows, and increased IoT-enabled monitoring of diagnostic instruments and reagents.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15623&type=smp

What Drivers Are Shaping The Development Of The Oncology Companion Diagnostics Market?

The anticipated future growth of the oncology companion diagnostics market is expected to be propelled by an increase in cancer cases. Cancer is defined as a complex group of diseases stemming from abnormal cells within the body that grow and spread uncontrollably. The rise in cancer incidents can be attributed to shifts in lifestyle, environmental factors, the obesity epidemic, tobacco consumption, and genetic predispositions. Oncology companion diagnostics play a vital role in precision medicine approaches within oncology, transforming cancer care by enabling personalized treatment selection, enhancing treatment effectiveness, minimizing adverse effects, facilitating clinical trial participation, and improving the monitoring of treatments. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that around 20 million new cases and 9.7 million cancer-related deaths were recorded annually in 2022, with predictions indicating that by 2040, there would be 15.3 million deaths and 29.9 million new cases per year. Therefore, the increasing number of cancer cases acts as a key driver for the oncology companion diagnostics market.

Which Segments Are Contributing To The Growth Of The Oncology Companion Diagnostics Market?

The oncology companion diagnostics market covered in this report is segmented –

1) By Product: Instrument, Consumables, Software

2) By Disease Type: Melanoma, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Other Disease Types

3) By Technology: Immunohistochemistry (IHC), In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH), Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies

4) By End User: Hospital, Pathology Or Diagnostic Laboratory, Academic Medical Center, Other End-Users

Subsegments:

1) By Instrument: Polymerase Chain Reaction (PCR) Instruments, Next-Generation Sequencing (NGS) Systems, Immunohistochemistry (IHC) Instruments, Fluorescence In Situ Hybridization (FISH) Instruments, Microarray Platforms

2) By Consumables: Reagents And Kits (DNA Or RNA Extraction Kits, PCR Reagents), Biopsy Needles, Testing Slides And Chips, Control And Calibration Samples

3) By Software: Data Analysis Software, Bioinformatics Software (For Gene Expression Analysis), Companion Diagnostic Decision Support Software, Clinical Workflow Management Software

Which Trends Are Influencing The Performance And Direction Of The Oncology Companion Diagnostics Market?

Leading companies within the oncology companion diagnostics market are concentrating on developing advanced high-throughput sequencing technologies, such as the deployment of c-MET companion diagnostic assays for therapeutic guidance in advanced non-small cell lung cancer, aiming to enhance precision oncology and individualize treatment selection. This implementation of c-MET companion diagnostic assays for therapeutic guidance in advanced non-small cell lung cancer involves the application of a targeted diagnostic test designed to detect c-MET gene alterations in patients suffering from advanced non-small cell lung cancer (NSCLC), thereby enabling clinicians to select appropriate therapies, optimize treatment efficacy, and support precision medicine approaches. As an illustration, in May 2025, NeoGenomics, Inc., an oncology testing company based in the US, introduced its c-MET CDx Assay to assist in guiding treatment decisions for individuals with advanced Non-Small Cell Lung Cancer (NSCLC). The c-MET CDx Assay functions as a companion diagnostic test designed to identify c-MET protein overexpression within tumor tissue, delivering rapid and accurate results to pinpoint patients who are likely to benefit from MET-targeted therapies. This assay is characterized by its high sensitivity and specificity, quick turnaround times, standardized testing procedures, and compatibility with routine clinical workflows, rendering it optimal for precision oncology and personalized treatment planning.

Who Are The Major Companies Operating In The Oncology Companion Diagnostics Market?

Major companies operating in the oncology companion diagnostics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, BGI Genomics Co. Ltd., Natera Inc., Myriad Genetics Inc., ARUP Laboratories, NeoGenomics Laboratories Inc., Guardant Health, Ambry Genetics Corporation, Biocartis SA, CENTOGENE N.V., Invivoscribe Inc., Pillar Biosciences Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Oncology Companion Diagnostics Market?

North America was the largest region in the oncology companion diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology companion diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oncology Companion Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15623&type=smp

Browse Through More Reports Similar to the Global Oncology Companion Diagnostics Market 2026, By The Business Research Company

Clinical Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Companion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795